期刊文献+

CYP4F2基因调控区G421C与原发性高血压的相关分析及鉴定 被引量:2

Correlation Analysis and Identification of G421C in Regulatory Region of CYP4F2 Gene with Essential Hypertension
暂未订购
导出
摘要 目的 探讨高血压候选基因CYP4F2基因调控区G421C多态位点与原发性高血压的相关性及其作用机制.方法 采用聚合酶链式反应-限制性片段长度多态方法检测196例高血压患者和219名正常对照者的G421C位点等位基因和基因型频率,报告基因检测CYP4F2基因G421C的启动子活性,凝胶阻滞实验鉴定G421C多态所在的Myb反应元件.结果 G421C位点的基因型和等位基因频率在原发性高血压和正常对照者间差异具有显著性(P<0.05),携带GG纯合子基因型的个体患病风险增高(OR=1.87,95%CI 1.11~3.13,P<0.05);421G等位基因启动子活性明显低于421C启动子(P<0.05);421G位点位于Myb反应元件中,而421C位点破坏了该基序.结论CYP4F2基因调控区的G421C多态与原发性高血压发生相关,421G等位基因通过与Myb反应元件结合抑制该基因的转录. Objective To investigate the correlation between G421 C polymorphism in the regulatory region of CYP4F2 gene and essential hypertension and its molecular mechanism. Methods Totally 196 hypertensive patients ( hypertension group) and 219 normotensive subjects ( control group) were genotyped by polymerase chain reaction-restriction fragment length polymorphism. The promoter activity with different alleles was evaluated by reporter assay. A Myb responsive element was identified using gel retardation assay. Results Significant differences were found in distribution of genotype and allele frequency of G421C between hypertension group and control group ( P 〈 0.05 ) , and homozygous GG genotype was independently associated with hypertension after adjustment for age, gender, body mass index, and other risk factors ( odds ratios 1.87, 95% CI 1.11-3. 13, P 〈 0. 05 ). 421G reporter construct showed decreased promoter activity compared with 421C reporter construct. 421G existed in Myb responsive element, whereas 421C damaged this motif. Conclusionu G421C polymorphism in the regulatory region of CYP4F2 gene is correlated with essential hypertension. 421G allele inhibits transcription by binding affinity of Myb responsive element.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2006年第2期143-147,共5页 Acta Academiae Medicinae Sinicae
基金 国家自然科学基金(30571027) 国家十五攻关项目(2004BA720A04)~~
关键词 CYP4F2基因 原发性高血压 Myb反应元件 CYP4F2 gene essential hypertension Myb responsive element
  • 相关文献

参考文献13

  • 1Lifton RP,Gharavi AG,Geller DS.Molecular mechanisms of human hypertension.Cell,2001,104(4):545-556.
  • 2Kikuta Y,Kusunose E,Kusunose M.Characterization of human liver leukotriene B4-hydroxylase P450 (CYP4F2).J Biochem,2000,127 (6):1047-1052.
  • 3Powell PK,Wolf I,Jin R,et al.Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450enzymes in human liver:involvement of CYP4F2 and CYP4A11.J Pharmacol Exp Ther,1998,285(3):1327-1336.
  • 4Lasker JM,Chen WB,Wolf I,et al.Formation of 20-hydroxyeicosatetraenoic acid,a vasoactive and natriuretic eicosanoid,in human kidney.Role of Cyp4F2 and Cyp4A11.J Biol Chem,2000,275 (6):4118-4126.
  • 5Roman RJ.P-450 metabolites of arachidonic acid in the control of cardiovascular function.Physiol Rev,2002,82 (1):131-185.
  • 6Gainer JV,Bellamine A,Dawson EP,et al.Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension.Circulation,2005,111 (1):63-69.
  • 7Guidelines Subcommittee.1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension.J Hypertens,1999,17 (2):151-183.
  • 8Andrews NC,Faller DV.A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.Nucleic Acids Res,1991,19 (9):2499.
  • 9Garcia A,LaMontagne K,Reavis D,et al.Determinants of sequence-specific DNA-binding by p48v-myb.Oncogene,1991,6 (2):265-273.
  • 10时景璞,王海龙,李辉,董卫,付凌雨,齐国先,贾志梅,杨慧英,宫伟,康辉,高旭光,王文利,姜玉山,李继光.辽宁省彰武县农村人群高血压患病率调查[J].中华流行病学杂志,2003,24(7):547-550. 被引量:61

二级参考文献10

共引文献60

同被引文献25

  • 1全国血压抽样调查协作组.中国各民族高血压患病情况调查[J].高血压杂志,1995,3(A01):24-30. 被引量:38
  • 2Hirani V,,Yarovoy A,Kozeska A,et al.Expression of CYP4F2 inhuman liver and kidney:assessment using targeted peptide antibo-dies. Archive of Biochemistry and Biophysics . 2008
  • 3Sanders RJ,Ofman R,Duran M,et al.Omega-oxidation of verylong-chain fatty acids in human liver microsomes.Implications forX-linked adrenoleukodystrophy. Journal of Biological Chemistry . 2006
  • 4Scott SA,Khasawneh R,Peter I,et al.Combined CYP2C9,VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics . 2010
  • 5Caldwell MD,Awad T,Johnson JA,et al.CYP4F2 genetic variantalters required warfarin dose. Blood . 2008
  • 6Perez-Andreu V,Roldan V,Anton AI,et al.Pharmacogenetic rele-vance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood . 2009
  • 7McDonald MG,Rieder MJ,Nakano M,et al.CYP4F2 is a vitaminK1 oxidase:An explanation for altered warfarin dose in carriers ofthe V433M variant. Molecular Pharmacology . 2009
  • 8Perez-Andreu V,Roldan V,Lopez-Fernandez MF,et al.Pharmaco-genetics of acenocoumarol in patients with extreme dose requirements. Journal of Thrombosis and Haemostasis . 2010
  • 9Wells PS,Majeed H,Kassem S,et al.A regression model to pre-dict warfarin dose from clinical variables and polymorphisms inCYP2C9,CYP4F2,and VKORC1:Derivation in a sample withpredominantly a history of venous thromboembolism. Thrombosis Research . 2010
  • 10Zordoky BN,El-Kadi AO.Effect of cytochrome P450 polymorphismon arachidonic acid metabolism and their impact on cardiovasculardiseases. Pharmacology and Therapeutics . 2010

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部